JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on May 17, 2004; DOI: 10.1124/jpet.103.063875


0022-3565/04/3102-642-647$20.00
JPET 310:642-647, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.063875v1
310/2/642    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Warner, T. D.
Right arrow Articles by Mitchell, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Warner, T. D.
Right arrow Articles by Mitchell, J. A.

INFLAMMATION AND IMMUNOPHARMACOLOGY

Cyclooxygenases 1, 2, and 3 and the Production of Prostaglandin I2: Investigating the Activities of Acetaminophen and Cyclooxygenase-2-Selective Inhibitors in Rat Tissues

Timothy D. Warner, Ivana Vojnovic, Francesco Giuliano, Rosario Jiménez, David Bishop-Bailey, and Jane A. Mitchell

The William Harvey Research Institute, Barts and the London, Queen Mary's School of Medicine and Dentistry, University of London, London, United Kingdom (T.D.W., I.V., F.G., R.J., D.B.-B.); and Department of Cardiothoracic Pharmacology, Unit of Critical Care Medicine, Imperial College London, Royal Brompton Hospital, London, United Kingdom (J.A.M.)

It has been suggested recently that cyclooxygenase-3, formed as a splice variant of cyclooxygenase-1, is the enzymatic target for acetaminophen. To investigate the relative roles of the putative three cyclooxygenase isoforms in different target tissues, we compared the inhibitory effects of acetaminophen, a cyclooxygenase-2-selective inhibitor; rofecoxib, a nonsteroid anti-inflammatory drug; naproxen; and a cyclooxygenase-1-selective inhibitor, SC560 [5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole]. Prostanoid production by aorta, heart, lung, and whole blood was inhibited by all drugs tested with the order of potency SC560 > naproxen > acetaminophen ≥ rofecoxib. In brain and cerebellum, no differences among drug potencies were found. Reverse transcription-polymerase chain reaction analysis of aorta, brain, cerebellum, heart, and lung showed general expression of cyclooxygenase-1 and cyclooxygenase-3 mRNA and particular expression of cyclooxygenase-2 mRNA in brain and cerebellum. Western blotting demonstrated general expression of cyclooxygenase-1 in test tissues and cyclooxygenase-2 within the brain and cerebellum. Western blotting using a commercially available antibody raised against canine cyclooxygenase-3 failed to detect any immunoreactive proteins. In conclusion, our studies indicate that cyclooxygenase-1 and cyclooxygenase-2 are the functional forms of the enzyme present in the rat tissues tested and that acetaminophen is not a selective inhibitor of "cyclooxygenase" activities in the central nervous system. This is consistent with the apparent impossibility for the expression of cyclooxygenase active protein from cyclooxygenase-3 mRNA in the rat. Also, our experiments show that the ability of rofecoxib to depress the circulating levels of prostaglandin I2 is more readily associated with its ability to reduce production from the lung, heart, or brain than from arterial vessels.


Received for publication December 5, 2003
Accepted May 17, 2004.

Address correspondence to: Prof. Timothy D. Warner, The William Harvey Research Institute, Barts and the London, Charterhouse Square, London EC1M 6BQ, United Kingdom. E-mail: t.d.warner{at}qmul.ac.uk




This article has been cited by other articles:


Home page
FASEB J.Home page
L. S. Harrington, R. Lucas, S. K. McMaster, L. Moreno, G. Scadding, T. D. Warner, and J. A. Mitchell
COX-1, and not COX-2 activity, regulates airway function: relevance to aspirin-sensitive asthma
FASEB J, November 1, 2008; 22(11): 4005 - 4010.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
B. Hinz, O. Cheremina, and K. Brune
Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man
FASEB J, February 1, 2008; 22(2): 383 - 390.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. Kis, J. A. Snipes, and D. W. Busija
Acetaminophen and the Cyclooxygenase-3 Puzzle: Sorting out Facts, Fictions, and Uncertainties
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 1 - 7.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. A. Snipes, B. Kis, G. S. Shelness, J. A. Hewett, and D. W. Busija
Cloning and Characterization of Cyclooxygenase-1b (Putative Cyclooxygenase-3) in Rat
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 668 - 676.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
B. Kis, J. A. Snipes, S. A. Simandle, and D. W. Busija
Acetaminophen-sensitive prostaglandin production in rat cerebral endothelial cells
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2005; 288(4): R897 - R902.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.